EMP2/XMP Full-Length Membrane Protein Products

Epithelial Membrane Protein 2 (EMP2), also known as XMP, is a small four-pass transmembrane protein of approximately 160 amino acids and belongs to the PMP22/EMP family. Unlike classical receptors with large extracellular domains, EMP2 contains relatively short extracellular and intracellular loops and lacks an obvious intracellular catalytic domain. Instead, its biological activity is closely linked to membrane localization and interactions with other membrane proteins. EMP2 regulates the cell-surface distribution of selected integrins and can modulate FAK/Src-associated signaling, thereby influencing cell adhesion, migration, invasion, angiogenesis, and membrane organization.

Aberrant EMP2 expression has been investigated in multiple malignancies, including glioblastoma, breast, ovarian, endometrial, and lung cancers. Anti-EMP2 antibodies have demonstrated antitumor activity in several preclinical tumor models, supporting EMP2 as an emerging therapeutic target. Direct EMP2-targeted drug development, however, remains largely preclinical. A notable recent example is FK002-exatecan, an EMP2-targeted antibody-drug conjugate reported in 2025 that showed potent antitumor activity in lung cancer cell lines, xenografts, and patient-derived models. Other approaches, including monoclonal antibodies, siRNA delivery, and immunomodulatory strategies, are also under investigation. Learn more about EMP2 biology and therapeutic development…

For this membrane-dependent target, DIMA BIOTECH provides full-length human EMP2 Synthetic Nanodisc proteins, including Human EMP2 full length protein-synthetic nanodisc (FLP100149) and Human EMP2-Strep full length protein-synthetic nanodisc (FLP120149). Both are expressed in HEK293 cells, while the Strep-tagged format carries C-terminal Flag and Strep tags and is supported by SDS-PAGE and ELISA validation data. The Synthetic Nanodisc format provides a membrane-like environment for full-length EMP2 and supports applications including EMP2 antibody discovery and screening, ELISA, SPR/BLI binding analysis, ADC antibody evaluation, and target validation.